Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS Kisqali for early breast cancer, Merck’s MRK Keytruda for malignant pleural...

AZN : 78.38 (-0.66%)
JNJ : 164.16 (-0.40%)
MRK : 117.17 (-0.05%)
LLY : 921.49 (+0.70%)
NVS : 115.94 (-0.03%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

ONCY : 0.9239 (-2.75%)
MRK : 117.17 (-0.05%)
NVS : 115.94 (-0.03%)
ONC.TO : 1.26 (-2.33%)
GLMD : 9.35 (+11.31%)
PFE : 29.42 (-0.81%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

ONCY : 0.9239 (-2.75%)
MRK : 117.17 (-0.05%)
NVS : 115.94 (-0.03%)
ONC.TO : 1.26 (-2.33%)
GLMD : 9.35 (+11.31%)
PFE : 29.42 (-0.81%)
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/CNW/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...

ONCY : 0.9239 (-2.75%)
NVS : 115.94 (-0.03%)
LNTH : 110.05 (+1.37%)
STRO : 3.77 (-3.83%)
ZYME : 13.09 (+0.31%)
ONC.TO : 1.26 (-2.33%)
Recent Breakthroughs in Cancer Research Could Impact These Key Companies

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – In the oncology world, there’s...

ONCY : 0.9239 (-2.75%)
ONC.TO : 1.26 (-2.33%)
NVS : 115.94 (-0.03%)
LNTH : 110.05 (+1.37%)
STRO : 3.77 (-3.83%)
ZYME : 13.09 (+0.31%)
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...

NVS : 115.94 (-0.03%)
PFE : 29.42 (-0.81%)
LLY : 921.49 (+0.70%)
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...

NVS : 115.94 (-0.03%)
PFE : 29.42 (-0.81%)
LLY : 921.49 (+0.70%)
BAYRY : 7.9900 (-1.11%)
Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...

NVS : 115.94 (-0.03%)
BIIB : 199.36 (-1.03%)
PFE : 29.42 (-0.81%)
LLY : 921.49 (+0.70%)
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).The SC formulation was approved under the brand name Tecentriq...

NVS : 115.94 (-0.03%)
RHHBY : 39.4500 (-0.03%)
LLY : 921.49 (+0.70%)
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry...

NVS : 115.94 (-0.03%)
RHHBY : 39.4500 (-0.03%)
PFE : 29.42 (-0.81%)
LLY : 921.49 (+0.70%)

Barchart Exclusives

3 Dividend Kings With Unstoppable Dividend Growth Potential
Discover three quality companies with healthy financials, low dividend payout ratios, and a history of incredible dividend growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar